Cargando…

Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis

BACKGROUND: Due to the presence of both classical estrogen receptor (ERα) and another ER subtype (ERβ) in ovarian cancer, hormonal treatment is an attractive option. However, response to tamoxifen in ovarian cancer is modest. The presence of ERβ variants further complicated the issue. We have recent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Karen K. L., Siu, Michelle K. Y., Jiang, Yu-xin, Wang, Jing-jing, Wang, Yan, Leung, Thomas H. Y., Liu, Stephanie S., Cheung, Annie N. Y., Ngan, Hextan Y. S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579953/ https://www.ncbi.nlm.nih.gov/pubmed/28859612 http://dx.doi.org/10.1186/s12885-017-3601-1

Ejemplares similares

Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer
por: Chan, Karen K. L., et al.
Publicado: (2018)

PFKFB3 Regulates Chemoresistance, Metastasis and Stemness via IAP Proteins and the NF-κB Signaling Pathway in Ovarian Cancer
por: Jiang, Yu-xin, et al.
Publicado: (2022)

PDK1 promotes ovarian cancer metastasis by modulating tumor-mesothelial adhesion, invasion, and angiogenesis via α5β1 integrin and JNK/IL-8 signaling
por: Siu, Michelle K. Y., et al.
Publicado: (2020)

Hexokinase 2 Regulates Ovarian Cancer Cell Migration, Invasion and Stemness via FAK/ERK1/2/MMP9/NANOG/SOX9 Signaling Cascades
por: Siu, Michelle K. Y., et al.
Publicado: (2019)

Molecular Biomarkers for the Early Detection of Ovarian Cancer
por: Zhang, Ruiqian, et al.
Publicado: (2022)

Aberrant Cholesterol Metabolism in Ovarian Cancer: Identification of Novel Therapeutic Targets
por: He, Jiangnan, et al.
Publicado: (2021)

Paradoxical Impact of Two Folate Receptors, FRα and RFC, in Ovarian Cancer: Effect on Cell Proliferation, Invasion and Clinical Outcome
por: Siu, Michelle K. Y., et al.
Publicado: (2012)

p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation
por: Siu, Michelle K. Y., et al.
Publicado: (2015)

Increased Expression of PITX2 Transcription Factor Contributes to Ovarian Cancer Progression
por: Fung, Frederic K. C., et al.
Publicado: (2012)

Orchestrated Action of AMPK Activation and Combined VEGF/PD-1 Blockade with Lipid Metabolic Tunning as Multi-Target Therapeutics against Ovarian Cancers
por: Yung, Mingo M. H., et al.
Publicado: (2022)

Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer
por: Wei, Na, et al.
Publicado: (2009)

Tumour Suppressive Function and Modulation of Programmed Cell Death 4 (PDCD4) in Ovarian Cancer
por: Wei, Na, et al.
Publicado: (2012)

New Insights into Ferroptosis Initiating Therapies (FIT) by Targeting the Rewired Lipid Metabolism in Ovarian Cancer Peritoneal Metastases
por: Zhan, Shijie, et al.
Publicado: (2022)

A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report
por: Ngu, Siew-Fei, et al.
Publicado: (2022)

Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-κB/IL-8 signalling in ovarian cancer
por: Jiang, Yu-Xin, et al.
Publicado: (2020)

Germline PALB2 Mutation in High-Risk Chinese Breast and/or Ovarian Cancer Patients
por: Kwong, Ava, et al.
Publicado: (2021)

Overexpression of Forkhead Box Protein M1 (FOXM1) in Ovarian Cancer Correlates with Poor Patient Survival and Contributes to Paclitaxel Resistance
por: Zhao, Fung, et al.
Publicado: (2014)

A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer
por: Wang, Jing-Jing, et al.
Publicado: (2021)

Human Papillomavirus Self-Sampling for Primary Cervical Cancer Screening in Under-Screened Women in Hong Kong during the COVID-19 Pandemic
por: Ngu, Siew-Fei, et al.
Publicado: (2022)

Aberrant Activation of ERK/FOXM1 Signaling Cascade Triggers the Cell Migration/Invasion in Ovarian Cancer Cells
por: Lok, Gabriel T. M., et al.
Publicado: (2011)

Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells
por: Chan, David W., et al.
Publicado: (2012)

Evaluation of an Isothermal Amplification HPV Assay on Self-Collected Vaginal Samples as Compared to Clinician-Collected Cervical Samples
por: Chan, Aaron H. Y., et al.
Publicado: (2023)

Patient-Initiated Follow-Up in Ovarian Cancer
por: Luk, Hiu Mei, et al.
Publicado: (2023)

Clinical performance of the Roche Cobas 4800 HPV test for primary cervical cancer screening in a Chinese population
por: Liu, Stephanie S., et al.
Publicado: (2022)

Metabolic active peritoneal sites affect tumor debulking in ovarian and peritoneal cancers
por: Tsoi, Tung Tung, et al.
Publicado: (2020)

Diagnostic Performance of Risk of Malignancy Algorithm (ROMA), Risk of Malignancy Index (RMI) and Expert Ultrasound Assessment in a Pelvic Mass Classified as Inconclusive by International Ovarian Tumour Analysis (IOTA) Simple Rules
por: Ngu, Siew Fei, et al.
Publicado: (2022)

Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer
por: Liu, Michelle X., et al.
Publicado: (2013)

Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis
por: Mo, Yulan, et al.
Publicado: (2023)

A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer
por: Helali, Aya El, et al.
Publicado: (2022)

Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade
por: Yung, Mingo M. H., et al.
Publicado: (2015)

The Stress-Inducible BCL2A1 Is Required for Ovarian Cancer Metastatic Progression in the Peritoneal Microenvironment
por: Liang, Rui, et al.
Publicado: (2021)

The interaction between C35 and ΔNp73 promotes chemo-resistance in ovarian cancer cells
por: Leung, T H-Y, et al.
Publicado: (2013)

Surgery including fertility-sparing treatment of GTD
por: Ngu, Siew-Fei, et al.
Publicado: (2021)

MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis
por: Mak, Celia S. L., et al.
Publicado: (2017)

Extremely stringent activation of p16(INK4a) prevents immortalization of uterine cervical epithelial cells without human papillomavirus oncogene expression
por: Hang, Su, et al.
Publicado: (2016)

Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface
por: Tang, Maggie K. S., et al.
Publicado: (2018)

Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells
por: Chen, Rain R., et al.
Publicado: (2019)

AMPK Activators Suppress Cervical Cancer Cell Growth through Inhibition of DVL3 Mediated Wnt/β-Catenin Signaling Activity
por: Kwan, H. T., et al.
Publicado: (2013)

Association of decreased mitochondrial DNA content with ovarian cancer progression
por: Wang, Y, et al.
Publicado: (2006)

Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers
por: Jiang, LiLi, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_291iak0bntuajo6lldehvu25gl